询 单
请 填 写 相 关 信 息
产品信息
产品名称
别名
CAS号
结构式 上传
联系方式
公司
联系人
电话
邮箱
内容
提交
中文版 English
请输入产品名称、CAS式、分子式
Methyl all-cis-5,8,11,14-eicosatetraenoate | CAS:2566-89-4
Methyl all-cis-5,8,11,14-eicosatetraenoate
  • 名称:全顺式-5,8,11,14-二十碳四烯酸甲酯 | Methyl all-cis-5,8,11,14-eicosatetraenoate
  • CAS号:2566-89-4
  • 别名:(5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic acid methyl ester
  • 分子式:C21H34O2
  • 分子量:318.49
  • EINESC号:219-900-1

产品描述

物理化学性质

沸点 200-205 ºC (1-2 Torr)**
闪点 102.0±24.0 ºC, 计算值*
密度 0.901±0.06 g/cm3 (20 º
折射率 1.4875 (589.3 nm 20 ºC)***

安全数据

没有数据没有数据

SDS

来源 SDS样本
没有数据没有数据
产品合成路线
更多

名称 CAS号
更多
文章
同行评议文献
The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.Keita Sugiura et al.Antimicrobial agents and chemotherapy, 58(7), 3837-3842 (2014-04-23) Ciclopirox olamine: a hydroxypyridone antifungal agent.B B Abrams et al.Clinics in dermatology, 9(4), 471-477 (1991-10-01) Thermogelling hydrogels of cyclodextrin/poloxamer polypseudorotaxanes as aqueous-based nail lacquers: application to the delivery of triamcinolone acetonide and ciclopirox olamine.Luis Nogueiras-Nieto et al.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 83(3), 370-377 (2012-12-04) Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.Anja Täuber et al.Molecular pharmaceutics, 11(7), 1991-1996 (2014-02-05) Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.Young Kim et al.In vivo (Athens, Greece), 25(6), 887-893 (2011-10-25) Mucoadhesive nanoliposomal formulation for vaginal delivery of an antifungal.Shaikh Karimunnisa et al.Drug development and industrial pharmacy, 39(9), 1328-1337 (2012-08-08) Antimycotic ciclopirox olamine in the diabetic environment promotes angiogenesis and enhances wound healing.Sae Hee Ko et al.PloS one, 6(11), e27844-e27844 (2011-11-30) Hypoxic ventilatory response in limited iron in the rat.M Pokorski et al.Journal of biological regulators and homeostatic agents, 26(4), 653-661 (2012-12-18) Hydration of nail plate: a novel screening model for transungual drug permeation enhancers.P Chouhan et al.International journal of pharmaceutics, 436(1-2), 179-182 (2012-06-19) Interaction between ciclopirox and acenocoumarol.José A Morales-Molina et al.European journal of clinical pharmacology, 69(3), 727-728 (2012-07-14) Determination of ciclopirox olamine in pharmaceutical products by capillary electrophoresis with capacitively coupled contactless conductivity detection.Fabiana Silva Felix et al.Electrophoresis, 32(8), 900-905 (2011-03-12) Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.Mark D Minden et al.American journal of hematology, 89(4), 363-368 (2013-11-26) Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.Siyuan Song et al.Cancer research, 71(24), 7628-7639 (2011-10-20) Photodynamic inhibition of Trichophyton rubrum: in vitro activity and the role of oxidative and nitrosative bursts in fungal death.Ludmila de Matos Baltazar et al.The Journal of antimicrobial chemotherapy, 68(2), 354-361 (2012-11-09) Development of ciclopirox olamine topical formulations: evaluation of drug release, penetration and cutaneous retention.Vanessa Alves Pinheiro et al.Pharmaceutical development and technology, 20(2), 197-203 (2013-11-30) Ciclopirox olamine: head to foot.F Emily Bell et al.Journal of drugs in dermatology : JDD, 2(1), 50-51 (2003-07-11) Competitive displacement of drugs from cyclodextrin inclusion complex by polypseudorotaxane formation with poloxamer: implications in drug solubilization and delivery.Luis Nogueiras-Nieto et al.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 80(3), 585-595 (2011-12-21) Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide.Christiane M Koller et al.Anticancer research, 33(6), 2435-2440 (2013-06-12) Case report: onychomycosis due to Trichophyton schoenleinii.Anna B Macura et al.Mycoses, 55(2), e18-e19 (2011-07-21) Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.Tsuyoshi Shimamura et al.Antimicrobial agents and chemotherapy, 55(7), 3150-3155 (2011-05-11) [Candida glabrata : pathogenicity and therapy update].H-J Tietz Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 63(11), 868-871 (2012-08-29) Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.S G Jue et al.Drugs, 29(4), 330-341 (1985-04-01) Targeting the Wnt/beta-catenin pathway in multiple myeloma.Leonard Christopher Schmeel et al.Anticancer research, 33(11), 4719-4726 (2013-11-14) A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.Ken Fujimura et al.Cancer research, 74(22), 6671-6681 (2014-09-28) Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation.D Monti et al.The British journal of dermatology, 165(1), 99-105 (2011-03-18) Oligodendrocytes Provide Antioxidant Defense Function for Neurons by Secreting Ferritin Heavy Chain.Chaitali Mukherjee et al.Cell metabolism, 32(2), 259-272 (2020-06-13) [When the nail is the polished one]. MMW Fortschritte der Medizin, 154(10), 24-24 (2012-07-19) Onychomycosis due to Neoscytalidium treated with oral terbinafine, ciclopirox nail lacquer and nail abrasion: a pilot study of 25 patients.Ígor B Cursi et al.Mycopathologia, 175(1-2), 75-82 (2012-09-15) Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects.D Monti et al.Journal of the European Academy of Dermatology and Venereology : JEADV, 27(2), e153-e158 (2012-03-28) Recurrent vulvovaginal candidosis: focus on the vulva.Florian C Beikert et al.Mycoses, 54(6), e807-e810 (2011-05-28) The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy.S J Weir et al.Journal of clinical pharmacy and therapeutics, 36(2), 128-134 (2011-03-04) Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.Siddhartha Sen et al.Experimental hematology, 41(9), 799-807 (2013-05-11) Standardization of hyphal growth inhibition rate as a means of evaluating Microsporum spp. in vitro susceptibility to terbinafine, griseofulvin, and ciclopiroxolamine.Fernanda Simas Corrêa Biancalana et al.Mycopathologia, 172(4), 279-285 (2011-05-26) Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.Sergio Schalka et al.Anais brasileiros de dermatologia, 87(1), 19-25 (2012-04-07) Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis:a randomized, double-blind, comparative study.Christian Diehl et al.Journal of drugs in dermatology : JDD, 12(3), 312-315 (2013-04-03) Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.Mark D Minden et al.American journal of hematology, 89(4), 363-368 (2013-11-26) Photodynamic inhibition of Trichophyton rubrum: in vitro activity and the role of oxidative and nitrosative bursts in fungal death.Ludmila de Matos Baltazar et al.The Journal of antimicrobial chemotherapy, 68(2), 354-361 (2012-11-09) Development of ciclopirox olamine topical formulations: evaluation of drug release, penetration and cutaneous retention.Vanessa Alves Pinheiro et al.Pharmaceutical development and technology, 20(2), 197-203 (2013-11-30) Ciclopirox olamine: head to foot.F Emily Bell et al.Journal of drugs in dermatology : JDD, 2(1), 50-51 (2003-07-11) Competitive displacement of drugs from cyclodextrin inclusion complex by polypseudorotaxane formation with poloxamer: implications in drug solubilization and delivery.Luis Nogueiras-Nieto et al.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 80(3), 585-595 (2011-12-21) Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide.Christiane M Koller et al.Anticancer research, 33(6), 2435-2440 (2013-06-12) Onychomycosis due to Neoscytalidium treated with oral terbinafine, ciclopirox nail lacquer and nail abrasion: a pilot study of 25 patients.Ígor B Cursi et al.Mycopathologia, 175(1-2), 75-82 (2012-09-15) Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.Elvira Sondo et al.American journal of physiology. Cell physiology, 301(4), C872-C885 (2011-07-15) Determination of ciclopirox olamine in pharmaceutical products by capillary electrophoresis with capacitively coupled contactless conductivity detection.Fabiana Silva Felix et al.Electrophoresis, 32(8), 900-905 (2011-03-12) Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.Tsuyoshi Shimamura et al.Antimicrobial agents and chemotherapy, 55(7), 3150-3155 (2011-05-11) Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.Siyuan Song et al.Cancer research, 71(24), 7628-7639 (2011-10-20) The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.Keita Sugiura et al.Antimicrobial agents and chemotherapy, 58(7), 3837-3842 (2014-04-23) Comparison of visual assessments versus planimetry assessments in a large-scale clinical trial of onychomycosis.Aditya K Gupta et al.The Journal of dermatological treatment, 25(3), 256-259 (2012-05-30) The safety and efficacy of ciclopirox olamine for the treatment of seborrheic dermatitis.Agron Starova et al.Expert opinion on drug safety, 4(2), 235-239 (2005-03-30) Antimycotic ciclopirox olamine in the diabetic environment promotes angiogenesis and enhances wound healing.Sae Hee Ko et al.PloS one, 6(11), e27844-e27844 (2011-11-30) Fungicidal drugs induce a common oxidative-damage cellular death pathway.Peter Belenky et al.Cell reports, 3(2), 350-358 (2013-02-19) Tinea corporis bullosa due to Trichophyton schoenleinii: case report.Mihai Mareş et al.Mycopathologia, 174(4), 319-322 (2012-05-12) Hydration of nail plate: a novel screening model for transungual drug permeation enhancers.P Chouhan et al.International journal of pharmaceutics, 436(1-2), 179-182 (2012-06-19) Interaction between ciclopirox and acenocoumarol.José A Morales-Molina et al.European journal of clinical pharmacology, 69(3), 727-728 (2012-07-14) Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.Elvira Sondo et al.American journal of physiology. Cell physiology, 301(4), C872-C885 (2011-07-15) Comparison of visual assessments versus planimetry assessments in a large-scale clinical trial of onychomycosis.Aditya K Gupta et al.The Journal of dermatological treatment, 25(3), 256-259 (2012-05-30) The safety and efficacy of ciclopirox olamine for the treatment of seborrheic dermatitis.Agron Starova et al.Expert opinion on drug safety, 4(2), 235-239 (2005-03-30) Fungicidal drugs induce a common oxidative-damage cellular death pathway.Peter Belenky et al.Cell reports, 3(2), 350-358 (2013-02-19) Tinea corporis bullosa due to Trichophyton schoenleinii: case report.Mihai Mareş et al.Mycopathologia, 174(4), 319-322 (2012-05-12) Standardization of hyphal growth inhibition rate as a means of evaluating Microsporum spp. in vitro susceptibility to terbinafine, griseofulvin, and ciclopiroxolamine.Fernanda Simas Corrêa Biancalana et al.Mycopathologia, 172(4), 279-285 (2011-05-26) Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.Sergio Schalka et al.Anais brasileiros de dermatologia, 87(1), 19-25 (2012-04-07) Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis:a randomized, double-blind, comparative study.Christian Diehl et al.Journal of drugs in dermatology : JDD, 12(3), 312-315 (2013-04-03) Hypoxic ventilatory response in limited iron in the rat.M Pokorski et al.Journal of biological regulators and homeostatic agents, 26(4), 653-661 (2012-12-18) Ciclopirox olamine: a hydroxypyridone antifungal agent.B B Abrams et al.Clinics in dermatology, 9(4), 471-477 (1991-10-01) Thermogelling hydrogels of cyclodextrin/poloxamer polypseudorotaxanes as aqueous-based nail lacquers: application to the delivery of triamcinolone acetonide and ciclopirox olamine.Luis Nogueiras-Nieto et al.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 83(3), 370-377 (2012-12-04) Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.Anja Täuber et al.Molecular pharmaceutics, 11(7), 1991-1996 (2014-02-05) Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.Young Kim et al.In vivo (Athens, Greece), 25(6), 887-893 (2011-10-25) [When the nail is the polished one]. MMW Fortschritte der Medizin, 154(10), 24-24 (2012-07-19) [Candida glabrata : pathogenicity and therapy update].H-J Tietz Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 63(11), 868-871 (2012-08-29) Mucoadhesive nanoliposomal formulation for vaginal delivery of an antifungal.Shaikh Karimunnisa et al.Drug development and industrial pharmacy, 39(9), 1328-1337 (2012-08-08)
备注

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).

名称 CAS号

相关产品

相关资讯

热门标签
询 单
请 填 写 相 关 信 息
产品信息
产品名称
别名
CAS号
结构式 上传
联系方式
公司
联系人
电话
邮箱
内容
提交